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New drug compounds discovery has moved at an accelerated pace in recent years, with a 
considerable focus on the transition from in vitro to in vivo models. As a result, there has 
been a significant increase in the need to adapt and develop novel non-invasive, high 
resolution in vivo imaging approaches for studying disease development and quantitatively 
determining molecular and cellular events in vivo. Non-invasive imaging methods allow 
continuous monitoring of disease development in vivo. For example, real time spatial-
temporal analysis of tumour growth can reveal the dynamics of cancer progression. 
Furthermore, the effects of therapy can be evaluated non-invasively in vivo. These 
approaches offer the ability to perform repetitive observations and interventions of the 
biological processes underlying disease development and progression.  
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to obtain biochemical functional information for the early 
characterization of the molecular alterations and, in turn, to improve diagnosis and therapy 
for clinical applications. 
Despite significant progress in developing rapid and accurate ex-vivo medical diagnostic 
tests, it is still essential to investigate approaches for in vivo non-invasive imaging because 
many human diseases and the outcomes of therapy not always and not easily can be 
determined by the analysis of blood samples or biopsies. For instance, whether a tumor 
shrinks during cancer therapy has to be determined by bioimaging modalities. In addition, 
non-invasive imaging techniques enable the examination of cellular and biomolecular 
events in locations that are difficult to access by any other means. 
Thus, the development of imaging agents with high sensitivity, high specificity, and low 
toxicity is necessary to improve diagnosis and therapy for clinical applications. 
In this perspective an emerging attractive class of targeting molecules is represented by 
short single-stranded oligonucleotides ligands, named aptamers, being able to bind with 
high affinity to specific protein or non-protein targets by folding into complex tertiary 
structures. They discriminate between closely related targets and are characterised by high 
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specificity and low toxicity thus representing a valid alternative to antibodies for in vivo cell 
recognition. Owing to their relatively small size in comparison to antibodies, aptamers 
should be better-suited for rapid target tissue penetration and blood clearance. In addition, 
different from antibodies, aptamers are chemically synthesized at low cost with high batch 
fidelity, are sufficiently stable and can be readily chemically modified to further enhance 
their stability, bioavailability and pharmacokinetics. Moreover, aptamer immunogenicity 
has never been reported. These properties indicate a great potential of aptamers as imaging 
agents, especially when compared to antibodies. 
The present chapter will be dedicated to aptamer-based molecular imaging modalities by 
reviewing the recent application of aptamers as ligands for inflammation imaging, 
thrombus imaging and tumour imaging. 
2. In vivo non-invasive imaging  
The functional imaging techniques developed in the past decades have given raised to 
powerful biomedical imaging tools that permit repeated non-invasive assessment and 
quantification of specific biological and pharmacological processes at the molecular level in 
human and animal (Lyons, 2005). 
By employing medical image modalities one can assess the physiological activities within a 
certain tissue or organ choosing among the imaging platforms available: positron-emission 
tomography (PET), single photon emission computed tomography (SPECT), nuclear 
magnetic resonance imaging (NMRI), optical imaging (OI) and computed tomography (CT). 
2.1 The emission tomography  
The emission tomography is based on the decay process of a specific radioactive element to 
detect the isotope distribution within the body as function of the time. The radionuclide 
concentration changes with time as consequence of the decay events as well as for the 
biochemical processes kinetics. Moreover the concentrations of tracer imaged the given 
tissue metabolic activity, in terms of the specific molecules of interest uptake (Massoud et al. 
2003). Differently from radio-diagnostics methods, more directed towards a morphologic 
analysis, emission tomography hold an essential rule in field of diagnostic and functional 
analysis (heart attack, epilepsy, cardiopathy, Parkinson disease).  
The compound tracer-ligand, which is of interest for its chemical binding properties to 
certain types of tissues, is injected into the body and depending on the nature of the 
radionuclide the decay product can be a photon (SPECT) or a positron (PET).  
The radioactivity profiles obtained are processed by an electronic calculator by means of 
appropriate reconstruction algorithms for the reconstruction of the tomographic image of 
the studied section. 
SPECT imaging is a quite new survey technique by which it is possible to reconstruct 
scintigraphic images related to the spatial and temporal distribution of a radioactive 
substance. SPECT equipment consists of one or more rotational gamma chambers which 
detect gamma rays, in the energy range between 80 KeV and 300 KeV, emitted from gamma-
emitting radioisotopes (99mTc, 111I, 123I, 131I, 125I), previously injected into the patient. The use 
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of targeted radiolabeled ligands to determine the tissue distributions of receptors allows the 
detection of disease upon imaging with a gamma-camera. Multiple 2D image projection can 
be acquired at different angles resulting in the visualization of the 3D biodistribution of the 
radionuclides. The spatial resolution of the reconstructed image depends on the number of 
angular and linear samples selected besides on the collimator and the tomographic 
reconstruction parameters. 
PET is the most extensively used technique in the field of clinical oncology, neurology and 
cardiology (Cantore et al., 2011). In the same way of SPECT, this technique is based on the 
use of radio labelled compounds which are injected into the living subject (usually into 
blood circulation). Especially useful to assess the degree of changes in the cellular 
metabolism as well as in their anatomic structure and in the dimension of the tumor mass, it 
plays a fundamental role in the screening, early detection, diagnosis and treatment of 
neoplasms (Langen et al., 2011). This powerful technique supplies the most advanced and 
outstanding tools on monitoring the early results of a tumor treatment plan giving the 
evidence on the success of the treatment itself and so avoiding useless chemotherapy cycles.  
Radionuclides used in PET scanning, typically isotopes with short half-lives ( 11C, 13N, 15O , 
18F) which undergo positron emission decay, are incorporated either into compounds 
normally used by the body such as, glucose, water, ammonia, or into molecules that bind to 
receptors. PET apparatus is made up of a detector block (scintillator crystal and 
photomultiplier) and a detectors ring which detects the two 511 keV gamma photons 
emitted in coincidence at 180 degrees to each other further to positron-electron annihilation 
events. By this means it is possible to localize their source along a straight line of 
coincidence. Following the radiotracers journey inside the body or the organs it is possible 
to trace its biological pathway and collect data for analysis. During the scan a record of 
tissue concentration is made as the tracer decays. The radiological image obtained is a 
fingerprint of the functionality of the examined organs. Even though PET and SPECT are 
similar there are remarkable differences in terms of efficiency and resolution. Due to the 
detection methodology, since emissions are detected "coincident" in time, PET scanner 
provides more radiation events and localization information, thus giving higher resolution 
images than SPECT, about 4-5mm against 7-8mm. In terms of efficiency only 1 to 10 photons 
upon 10.000 emitted can be detected with SPECT while PET efficiency is about 100 times 
higher (pmoles vs nanomoles).  
Small animals SPECT can provide resolutions up to 200 micrometer (Acton & Kung, 2003). 
Sensitivity, resolution, and field of view are dependent upon the pinhole collimator of the 
instrument. On the other end small animals PET scanner can provide lower spatial 
resolution (0.6 mm). PET is best suited for small molecules and molecules with fast 
kinetics. Moreover PET tracers have lower specific activity, shorter half-lives and are more 
difficult to synthesize. Finally PET radiation dose is 10 fold higher than SPECT (Larobina 
et al., 2006).  
2.2 Nuclear magnetic resonance imaging 
NMRI is a medical imaging technique based on nuclear magnetic resonance to image nuclei 
of atoms inside the body and is able to distinguish pathologic tissue from normal tissue 
(Schellenberger, 2004). This technique is widely used in radiology as it provides good 
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contrast between the different soft tissues of the body in addition to a high images quality. 
Based on the use of strong magnetic fields and non-ionizing radiation, radio frequency 
range, NMRI is completely harmless to the patient. 
Differences of nuclei behavior subject to a strong magnetic field gradient can be recorded to 
construct an image of the scanned area of the body resulting in the visualization of detailed 
internal structures. In the classical representation of an atom nucleus is depicted as a 
rotational sphere along an axis. This rotational motion is associated with a physical quantity 
called: angular momentum (spin). Because of the nuclear composition the so called 
rotational sphere is positively charged resulting in the generation of a magnetic field as a 
consequence of charge motion. By this means nuclei possess an intrinsic angular momentum 
(spin) associated to a magnetic momentum. The spin of a charged particle is associated with 
a magnetic dipole momentum by a proportional factor called gyromagnetic factor. The g-
factor is a characteristic of each nucleus. Allowed values of spin are 0, 1/2, 1, 3/2, 2, etc., 
which corresponds to certain magnetic momentum values according to a specific 
proportional relationship. The sensitivity by which a nucleus can be detected with NMR 
depends on the g-factor. Nuclei with a high gyromagnetic ratio will be easily examined. 
Nuclei with spin value equal to zero, null magnetic momentum, are “transparent” to 
external magnetic field so they can not be analyzed with NMR. Therefore only atoms with 
an odd number of nucleons (protons and/or neutrons) resulting in a nonzero nuclear spin 
can be chosen for this methodic. In the presence of a magnetic field sample nuclear spins, 
randomly arranged, will align along the external field lines (polarization), absorbing and re-
emitting electromagnetic radiation at a specific resonance frequency which depends on the 
strength of the magnetic field and on the magnetic properties of the sample atoms. For a set 
value of magnetic field applied, different nuclei give rise to distinct resonant frequencies 
depending on the strength of applied field. If a sample is placed in a non-uniform magnetic 
field then the resonance frequencies of the sample's nuclei depend on where in the field they 
are located. In the NMRI techniques the polarization of the magnetic nuclear spins is 
achieved by exposing the sample to a constant static magnetic field. The following step is 
the perturbation of this alignment by employing an electro-magnetic, usually radio 
frequency (RF), pulse. The required perturbing frequency is dependent upon the static 
magnetic field and the nuclei of observation. When the RF pulse is turned off nuclear spins 
at different locations relaxes to the equilibrium state with consequent emission of 
characteristic frequencies detectable by the scanner. The electromagnetic signals shifts 
induced by strong field gradients are recorded to construct tridimensional images of studied 
area. To maximize the NMR signal strength the two fields are usually chosen to be 
perpendicular to each other. 
NMRI uses intense applied magnetic fields in order to achieve dispersion and very high 
stability to deliver spectral resolution. The spatial resolution of the imaging technique 
depends on the magnitude of magnetic field gradient. Very high resolution images, on the 
order of one tenth of millimeter, can be achieved with a 3 Tesla scanners.  
For mouse MRI imaging can achieve 10-100 micrometer spatial resolution, with preferably 
at least 7.0 Tesla. To enhance the appearance of blood vessels, tumors or inflammation, 
contrast agents, properly modified, may be injected intravenously acting as specific 
molecular probe. This opens the possibility to monitor in vivo cellular functions as well as 
get information on the spatial distribution of a specific molecular target (Percy et al., 2011). 
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The employment of stable isotopes as contrast agents, diversely from PET methodology, 
gives to this technique the great advantage of supervising metabolic pathways or receptors 
dynamic for infinite time. 
2.3 Optical Imaging  
This non-ionizing imaging technique is based on the use of electromagnetic radiation in the 
near-infrared and visible field to observe single-molecule in living cells. Cost-effective, 
rapid, easy to use, optical imaging can be readily applied to studying disease processes and 
biology in vivo (Luker & Luker, 2008). A charge-coupled device camera (CCD camera) 
detects light emitted allowing for real time 2D imaging and 3D reconstruction. The key 
feature is the different behavior of light interaction with tissues such as adsorption, 
emission, excitation, scattering, fluorescence and luminescence. 
Molecular targets labeled with nanodiamonds, fluorescent dyes, quantum dots, as well as 
bioluminescent, chemiluminescent and fluorescent reporters, would enable biomolecule 
tracking inside cells (Rong Tong et al., 2010). Fluorescently labeled antibodies or biomarkers 
can target and identify tumors or other diseases in in vivo modalities (van der Meel et al., 
2010). Molecular and biochemical events such as transgene expression, transforming 
phenotype and enzyme activity can be detected by means of fluorescent probes. Tumor 
cells, stem cells, immunological cells can be transfected to overexpress luminescent or 
fluorescent proteins (Pomper, 2005). Widely used in animal models trial for low costs and 
good sensitivity (pmol concentrations, few cells), optical labeling technology scanner has an 
anatomical resolution relatively poor (1mm) due to scattering of light in tissue (Hickson, 
2009). OI has a minimal use in clinic owing to limited depth profiling (couple of centimeters 
in tissue depth) (Leblond et al., 2010). 
2.4 Computed tomography 
X-ray computed tomography (CT) is a radiological technique which provides high spatial 
resolution (less than 1 mm) of morphological imaging; three-dimensional anatomical 
images. Axial sections of well-defined depth are imaged upon differential x-ray absorption 
by different tissues. CT is based on detection of an X-ray beam by means of detectors system 
which converts the attenuated beam intensity into electric pulse of equivalent value.  
By interaction with electrons of the material probed, photons are removed from the incident 
beam. The total energy of the resulting beam is then attenuated. The higher the electron 
density, the more interaction of X-ray with the sample material occurs and the more 
attenuated is the final energy. Because of the inherent high-contrast resolution of CT, 
differences between tissues that differ in physical density by less than 1% can be 
distinguished. The CT methodology is widely use in medicine as a diagnostic tool: detailed 
studies of bone and joint structure, bone metastasis scans, measurement of tumor size and 
location, and visualization of airway structure in the lungs, can be assess with high 
resolution. The major drawback of the technology is the high radiation dose which can be 
lethal or mutagenic. For imaging systems dedicated to in vivo studies in animal models, the 
optimal resolution is 50–100 micrometer. Specimen instruments have resolutions down to 
less than 10 micrometer and can visualize e.g. trabecular bone structure. 
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3. Aptamers as excellent targeting molecules for in vivo imaging  
Aptamers are single-stranded oligonucleotides (DNA or RNA) that like peptides or 
monoclonal antibodies, bind to their targets by complementary shape interactions. Indeed, 
aptamers function by folding into unique globular three-dimensional conformation that 
dictates high-affinity and specificity binding to a variety of targets, each structure being 
unique and determined by the sequence of the nucleic acid (Figure 1 A). As discussed in this 
chapter, the advantages of using nucleic acid aptamers for imaging/therapy are their 
favourable pharmacokinetic properties (rapid renal clearance) and their excellent affinity 
and specificity for their targets. These properties render aptamers useful targeting molecules 
for in vivo imaging allow obtaining high-resolution images with high signal-to-noise ratios 
and decreasing non-specific targeting thus reducing toxicity to non-target tissues (Tavitian 
et al., 1998, 2009; Perkins & Missailidis, 2007). 
 
Fig. 1. The size of each slice is related to the resolution of the indicated technique; the colour 
scale is proportional to the cost (clockwise). 
3.1 Aptamers production 
Aptamers are generated by an in vitro evolutionary selection-amplification scheme, named 
SELEX (Systematic Evolution of Ligands by EXponential enrichment) from libraries of 
random sequence oligonucleotides of large sequence complexity (generally between 1013 
and 1015 members) (Ellington & Szostak, 1990; Tuerk & Gold, 1990). As schematized in 
Figure 1 B, a typical SELEX experiment includes reiterated rounds of: (1) incubating the 
library with the target molecule; (2) partitioning nucleic acids bound specifically to the 
target molecule from unbound sequences; (3) dissociating the nucleic acid-protein 
complexes; and (4) amplifying of the nucleic acids pool enriched for specific ligands. After 
the final round, the PCR products are cloned and sequenced to subsequently identify the 
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best binding sequences. Due to the fact that the specific, three-dimensional arrangements of 
a small number of contact points of the aptamer mediates the target-aptamer interaction, 
rather than a general affinity for the sugar-phosphate backbone of the nucleic acid, aptamers 
can achieve high target selectivity. In addition, the binding characteristics of aptamers can 
be influenced by the type of the experimental system used for the selection and counter-
selection (depletion of aptamers that bind to non-target molecules). As a result, aptamers 
bind their own target with sub-nanomolar affinity thus revealing useful for many of the 
applications for which antibodies are already employed because of their own definite 
characteristics: (i) capacity to discriminate among closely related targets (e.g., will typically 
not bind other proteins from the same gene family); (ii) capacity to quantify the level of 
expression of the protein target; (iii) through binding, may act as inhibitors to block the 
activity of the target product. More important, they are usable not only for in vitro but also 
for in vivo purposes since they are sufficiently stable and can be readily chemically modified 
to further enhance their stability, bioavailability and pharmacokinetics (Esposito et al., 2011; 
Keefe et al., 2008, 2010). 
 
Fig. 2. Schematic representation of SELEX technology. The RNA/DNA aptamer library 
contains a variable region flanked by two constant regions. These constant regions include 
primer sites for PCR amplification and a consensus promoter for the T7-RNA polymerase 
(in the case of an RNA library). The library is used for the selection process. The target can 
be a purified recombinant protein (Protein-SELEX) or a complex target as entire living cells 
(cell-SELEX) 
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3.2 Systemic clearance of the aptamers 
Furthermore, due to their relatively small size (8-15 kDa) in comparison to antibodies (150 
kDa), aptamers should be better suited for rapid tissue penetration and blood clearance, two 
excellent characteristics for contrast agents in imaging. Indeed, when antibodies bind their 
target, their slow clearance may necessitate waiting for days before a significant signal 
emerges from the background of excess unbound ligand. This of course often results in 
organ toxicity and, in addition, limits the usefulness of imaging technology in diagnosing 
acute conditions, and precludes the use of short-lived radionuclides. 
On the contrary, aptamers not conjugated to polyethylene glycol (PEG) are cleared very 
quickly from blood circulation because of renal excretion and hepatobiliary clearance. A 
typical short, nuclease-resistant oligonucleotide administered intravenously exhibits an in 
vivo half-life of <10 min, unless filtration can be blocked by either facilitating rapid 
distribution out of the blood stream into tissues or by increasing the apparent molecular 
weight of the oligonucleotide above the effective size cut-off for the glomerulus. In addition, 
immunogenicity has been found to be either absent or limited when 1000-fold higher doses 
of an aptamer (than would be required clinically) were administered to monkeys (Foy  
et al., 2007). 
This property depends on the fact that antibodies to synthetic oligonucleotides are not 
generally produced and, in addition, the innate immunity response against non-self RNAs 
does not hinder aptamer therapy because 2’-modified nucleotides abrogate Toll-like 
receptors responses (Yu et al., 2009).  
3.3 Stability of the aptamers 
Prerequisites for a successful in vivo application of aptamers as molecular target imaging 
agents are represented by high affinity and selectivity to their target as well by adequate 
stability against in vivo degradation. Since oligonucleotides, especially RNAs, are rapidly 
degraded by nucleases in whole organisms, resulting in a very short half-life in the blood, a 
variety of approaches have been addressed to increase the stability of natural nucleic acids 
in biological media (Keefe & Cload, 2008). 
The most effective modifications to circumvent this limitation are the substitutions at the 2’-
ribose of the pyrimidines that are mainly affected by serum nuclease degradation. Initially, 
attention is focused on ‘post-SELEX modifications’, however, due to the fact that folding 
rules for single-stranded oligonucleotide regions change when these modifications are 
introduced, the binding properties of an aptamer selected in the presence of standard 
nucleotides might be completely different when the same sequence is synthesized with 
nucleotides containing a different 2’-substituent (Blank et al., 2001; Usman & Blatt, 2000; 
Aurup et al., 1992). To circumvent this limitation selections can be performed directly in the 
presence of 2’-modified nucleotides, as long as the modified nucleotides are accepted by T7 
RNA polymerase for the in vitro reaction steps of the selection (Aurup et al., 1992; Ruckman 
et al., 1998). RNA-aptamers containing 2′-fluoro and 2’-amino pyrimidine (2’-F-Py, 2’-NH2-
Py, respectively) can be generated performing the selection in the presence of 2’-modified 
nucleotides (Chelliserrykattil et al., 2004).Analogously, aptamers containing 2′-O-Metyl 
purines (2’-O-Me) have also been developed through post-SELEX modification steps or by 
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starting from 2’-O-Me–containing random sequence libraries during the SELEX process 
itself (Burmeister et al., 2004; Chelliserrykattil & Ellington, 2004). 
Even if 2’-modified nucleotides-containing aptamers show considerable increase in serum 
stability also in the absence of other modifications, changes in the internucleotide linkages 
(such as the use of phosphorothioate) and in the nucleobases (for example, the substitution 
of 5-position of uridine) as well the capping at the oligonucleotide 3′-terminus, have been 
reported (Keefe & Cload, 2008). 
Conformation flexibility is hypothesized to be a major factor limiting the affinity and 
specificity of interactions due to the entropic penalty upon binding. Furthermore, since 
single-stranded regions are the primary site of nuclease attack, the conformational flexibility 
would render the aptamer more accessible to nucleolytic degradation and thus, reduction of 
flexibility would be a key prerequisite for successful in vivo application. One way to stabilize 
aptamers is to increase thermal stability of double-stranded areas located within non-
binding regions. In this respect, the use of locked nucleic acids (LNA), containing a 
methylene bridge to connect the 2′-O to the 4′-C, increases the stability of base pairing 
stabilizing the duplex and enhancing the resistance to nuclease. For example the 
introduction of LNA-modifications in the anti-tenascin C (TN-C) aptamer significantly 
improves its plasma stability of approximately 25% and enhances the tumor uptake 
(Schmidt et al., 2004). 
An interesting application of the SELEX process is based on the selection of RNA aptamers 
binding to the mirror-image of an intended target molecule (e.g. an unnatural D-amino acid 
peptide), followed by the chemical synthesis of the mirror-image of the selected sequence 
(Eulberg & Klussmann, 2003). As a consequence of molecular symmetry, the mirror-image 
aptamer (made from L-ribose) binds to the natural target molecule. Because of the 
substitution of the natural D-ribose with L-ribose, the mirror-image aptamer (named 
Spiegelmer) is totally stable. NOX-A12 and NOX-E36 are two spiegelmers actually in clinical 
trials for the treatment of hematologic tumors and complications of type 2 diabetes, 
respectively (Esposito et al., 2011; Ellington, 2010). 
4. Inflammation imaging with aptamers 
The assessment of precise and reliable methods for the diagnosis of inflammatory processes 
is an important goal in medicine for the effective management of inflammation-related 
diseases. Acute inflammatory diseases are characterized by a significant increase in the 
lymphocytes and neutrophils count in the peripheral blood while chronic inflammatory 
diseases are characterized by infiltration of the target organ by mononuclear cells, such as 
lymphocytes, plasma cells, and macrophages (Weiss, 1989).  
Some inflammatory processes, such as organ-specific autoimmune disorders, are difficult to 
diagnose because they either are asymptomatic or have non-specific symptoms. The 
possibility of diagnosing inflammatory processes during the early stage may allow for early 
therapeutic intervention and possible prevention of the disease. 
During inflammation, levels of several proteolytic enzymes are significantly increased 
including neutrophil elastase that is released by neutrophils accumulated at the site of 
inflammation (Doring, 1994). Aptamers as specific irreversible inhibitors of neutrophil 
www.intechopen.com
 Molecular Imaging 
 
104 
elastase have been isolated by ‘blended SELEX’, a modification of the basic SELEX 
technology that allows to confer high-affinity binding to a weak, covalent inhibitor of an 
enzyme (Smith et al., 1995; Charlton et al., 1997). 
In this process, a randomized nucleic acid library attached covalently to an inhibitory 
compound of elastase (a valyl diphenyl ester phosphonate) was used to select for a 
secondary, stabilizing contact for the target molecule. By iterative selection and 
amplification steps, the nucleic acid sequences that best promote the covalent reaction of the 
valyl phosphonate moiety with the active-site serine of elastase were identified. In addition 
to inhibiting elastase free in solution, these aptamers were highly effective at blocking 
degradation of elastin particles by activated neutrophils. Further, a truncated DNA aptamer 
version, named NX21909, was tested in a rat model of lung inflammation and was found to 
inhibit neutrophil infiltration by 53% at a dose of 40 nmol (Bless et al., 1997). Using 
fluorescent flow cytometry, the aptamer revealed able to bind preferentially to activated 
neutrophils (Charlton et al., 1997).  
The first example of the use of aptamers as in vivo imaging probes is represented by the use 
of NX21909 for diagnostic imaging of inflammation in a rat model of the reverse passive 
Arthus reaction induced by immune complex deposition (Charlton et al., 1997). The aptamer 
was labelled with 99mTc and given by intravenous injection 3.5-4 h after induction of 
inflammation. Rats were imaged on a gamma camera in 10 min frames continuously for 40 
min and additional 10 min frames were taken every hour up to 4 h after administration of 
imaging agent. 
Remarkably, a better signal-to-noise ratio was achieved by the aptamer compared to a 
clinically used IgG-based inflammation imaging agent used as a positive control (for the 
aptamer, a ratio of 4.3 ± 0.6 was achieved at 2 h; for IgG, a ratio of 3.1±0.1 was achieved at 3 
h). This ratio was achieved primarily by the rapid clearance of the aptamer from the 
peripheral circulation. thus indicating that the aptamer technology may be successfully 
applied to diagnostic imaging. 
5. Thrombus imaging with aptamers 
Thrombin is the last enzyme in the clotting cascade functioning to cleave fibrinogen to fibrin 
which forms the fibrin gel of a hemostatic plug or a pathologic thrombus. In addition to its 
role in blood coagulation, it also triggers important anticoagulant and antifibrinolytic 
pathways (Petäjä, 2011). The crystal structure of thrombin has been determined (Bode et al., 
1992; Stubbs & Bode, 1993) thus giving important insight into its structure-function 
relationship. DNA aptamers have been generated that bind to different domains of the 
protein. ODN1 binds to exosite 1, the thrombin substrate binding site, thus competing with 
fibrin for binding to the same site on thrombin (Bock et al., 1992; Wu et al., 1992). 
Conversely, ODN2 reacts with exosite 2, the heparin binding site on thrombin (Tasset et al., 
1997). These aptamers have been extensively characterised for their binding to thrombin and 
ODN1, is currently being evaluated in phase II clinical trials by ARCA 
Biopharma/Archemix Corp. as an anticoagulant for use during acute coronary artery 
bypass surgery. Being unmodified and unstable in vivo the aptamer, designated as Nu172, 
has to be administered by continuous intravenous infusion (Esposito et al., 2011). 
To generate thrombin-dependent images in aptamer-mediated thrombus imaging 
approaches, the radiolabeled aptamer must form a ternary complex with thrombin bound to 
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the fibrin matrix. For this reason ODN 2, but not ODN 1, has been used for thrombus 
imaging (Dougan et al., 2003). 
In vitro experiments showed that ODN2 can form a ternary complex (with thrombin and 
fibrin) in clots, a necessity for thrombus imaging, thus indicating that allosteric interference 
from the fibrin binding site (exosite 1) did not impede ODN 2 binding at exosite 2. 
Thrombin-dependent uptake of ODN 2 was observed with in situ labeling of clots and by 
labeling of preformed clots. Further, the retention of [125I]ODN 2 increased as the thrombin 
content of thrombi was increased whereas the rate of release of ODN 2 out of preformed 
thrombi decreased. Then, the aptamer was tested in vivo, in a rabbit jugular vein model 
using thrombus supplemented with human thrombin,. The labeled aptamer was introduced 
internally with the portion of rabbit blood, or else externally to a preformed unlabeled clot 
via the truncated facial vein and the thrombus area was imaged with a 2D scintigraphic 
camera, or excised for counting. Despite the clearly promising effect in vitro when ODN 2 
was tested in vivo, the uptake was equal to the ovalbumin control and did not reflect 
thrombin content. A possible explanation of the failure of the in vivo thrombin-dependent 
imaging was attributed to the rapid clearance of ODN 2 from blood, combined with slow 
mass transfer in the thrombus. It is conceivable that nucleic acid analogs with extended 
lifetimes in circulation might help overcome this problem. For instance, the clearance rates 
of aptamers can be altered to keep them in circulation by anchoring them to liposome 
bilayers, by coupling them to inert large molecules such as PEG or to other hydrophobic 
groups (Willis et al., 1998; Healy et al., 2004). 
It is noteworthy that the Food and Drug Administration (FDA)-approved aptamer, 
Macugen, as well as all the aptamers in clinical trials, except for Nu172, have been 
conjugated with PEG to enhance their half-life in vivo (Esposito et al., 2011). 
6. Aptamers as in vivo imaging reagents in cancer 
The aim of this section is to give a detailed overview on the aptamers developed for tumour 
imaging. Pointing out the attention on the structural modification as well as the 
bioconjugation with specific tags, we will focus on the experimental results emphasizing the 
essential requirements for potential application of aptamers as imaging probes for in vivo 
studies: high target specificity and affinity, rapid pharmacokinetics, exclusion of toxic side 
effects, tumour penetration, chemical stability, and high signal-to-noise ratio.  
Five modalities (PET, SPECT, NMRI, CT and OI) are available to the scientist for oncological 
investigations in animals (Lewis et al., 2002; Tavitian, 2003). PET and NMRI technologies 
offer deep tissue penetration and high spatial resolution, but compared with non-invasive 
small animal optical imaging, these techniques are very costly and time consuming to 
implement. Aptamers have been successfully coupled to different targeted radiolabeled 
ligands and contrast agents to generate probes for in vivo medical imaging by using the five 
modalities previously described. 
6.1 Aptamers conjugated with 99mTc for SPECT  
The TTA1 aptamer against TN-C has been generated by a crossover SELEX experiment that 
involves crossing from cell-SELEX on TN-C-positive U251 glioblastoma cells to protein-
SELEX against purified recombinant TN-C (Hicke et al., 2001).  
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To improve stability against plasma nucleases, therefore guarantee a good blood persistence 
leading to sufficient signal-to-noise ratios for imaging, aptamer backbone (2’-F-Py 
containing RNA, 39mer) has been modified with the addition of maximal 2’-OMe purine 
substitutions, a thymidine cap at the 3’ end and LNA in not binding critical stem (Shimdt et 
al., 2004). This TTA1 derivative has been further conjugated with mercapto-acetyl diglycine 
(MAG2) chelate via an hexyl-aminolinker at the 5’ end and labelled with 99mTc for 
performing single photon emission computed tomography (Hicke et al., 2006) . 
To assess the degree of stability, an essential feature to achieve a sufficient targeting and 
blood clearance, combined to low background activity in non-target organs, tumour to 
blood and tissue distribution of 99mTc-labeled aptamer have been examined in murine 
xenograft models of glioblastoma and breast cancer (Hicke et al., 2006). Images of 
glioblastoma and breast tumors were taken at various times after intravenous injection in 
mice using a γ-camera. After 3 h post injection the tumor mass was visible as well as liver 
and bladder. At 18h post injection the two major clearance pathways were entirely clean 
from any radioactivity, as predicted by biodistribution analysis (Table1), and the tumor was 
clearly visualized as blazing structure (Hicke et al., 2006). Data show a rapid renal and 
hepatobiliary clearance, 0.2 %ID/g and 1.5 %ID/g at 3h, respectively and a rapid tumor 
penetration (6% injected dose at 60 min). Tumor retention is durable (2.7% injected dose at 
60 min) and the tumor-to-blood signal is significantly high (Hicke et al., 2006). 
Substitution of DTPA-111In or insertion of a PEG3,400 linker have also been tested for 
biodistribution analysis showing a dramatic alteration of tissue uptake and clearance 
patterns, indicating that simple changes to chelator can have significant effects on tissue 
uptake and clearance patterns. 
DNA-aptamers that target cell-surface mucin 1 glycoprotein (MUC1), generated by Protein-
SELEX against purified MUC1 peptides (Ferreira et al., 2006), have also been labeled with 
99mTc (Ferreira et al., 2006). The aptamers, named AptA and AptB, have been selected 
against the protein core or the glycosylated protein, respectively. Various chelating agents 
have been conjugated to the aptamers and multi aptamer complexes have shown increased 
retention of the complex in circulation without increasing the immunogenicity of the 
complex or adversely altering its tumor penetration properties. The biodistribution data of 
the labeled products have shown differences that depend on the size of the conjugate and 
the type of ligand (Borbas et al., 2007). Four types of chelators have been coupled to anti-
MUC1 aptamers to generate a novel complex for diagnostic imaging with improved 
properties: MetCyc, MAG3, DOTA and 4 (Figure 3).  
Differently from the monomeric Tc-MetCyc-Apt and Tc-MAG3-Apt, the tetrameric 
compounds, DOTA and 4, conjugate with 99mTc are able to grab four aptamer molecules 
modified at 5’ by insertion of amine groups to facilitate coupling with the ligands carboxylic 
terminations and 3’ ends to protect against nuclease degradation. Both tetrameric and 
monomeric aptamers were tested in nude mice bearing xenografted MCF7 breast cancer 
tumor. Compared to the monomeric biomarker composites, DOTA and 4 showed an 
increased retention in the circulation by means of their largest molecular weight. Despite the 
tetrameric complexes showed improved tumor retention and pharmacokinetic properties 
compared to the monomeric compounds, biodistribution studies have exhibited presence of 
free technetium in the stomach and large intestine highlighting some kind of lack in the Tc-
aptamer binding (Borbas et al., 2007). 
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Fig. 3. Schematic representation of monomeric and tetrameric aptamer bioconjugates (see 
text for details). 
Anti-MUC1 aptamers have also been successfully conjugated to MAG2chelator and the 
complexes have been labeled with 99mTc (Pieve et al., 2009). Analysis of two aptamer–
radionuclide conjugates, AptA and AptB, biodistribution properties in MCF7 xenograft-
bearing nude mice shows strong 99mTc binding properties (70-80% for AptA and ≥80% for 
AptB) and high stability in vivo, in terms of nuclease degradation and leaking of the metal 
(Table 1). Both aptamers show a maximum tumor uptake after 5h post injection, even 
though Apt B has higher accumulation rate, 0.12 %ID/g (for AptA) and 0.14 %ID/g (for 
AptB), followed by a decrease at 16h, 0.033 %ID/g (for AptA) and 0.016 %ID/g (for AptB) 
and 22h, 0.008 %ID/g (for AptA) and 0.013 %ID/g (for AptB). As pointed out by these data 
AptB releases quicker from the target keeping his activity constant between 16h and 22h, 
whilst AptA activity decreases constantly in time. The activity discrepancy is consequence 
of a different kinetic behaviour upon binding with the molecular target. AptB, in fact, 
internalized in the cancer cell quicker than AptA. Table 1 shows tumour-to-blood ratios 
values, taken at different times post injection, of both oligonucleotide carriers, confirming 
the assumption of Missailidis’s group. The maximum levels of tumour uptake and clearance 
has reached at 5h post injection for AptA and AptB (table 1) but whiles the tumour-to-blood 
ratio trend of AptB, after 5h, is constant in time, AptA decreases drastically at 16 h, reaching 
his minimum value, and increases again at 22h, suggesting that the bound aptamer was not 
internalized.  
Even if the radiolabeled aptamers demonstrate good tumor uptake and clearance, they 
require further optimization before diagnostic use. 
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Aptamer TTA1/2’Fy-RNA AptA/DNA AptB/DNA 
Length(nt) 39 25 25 
Kd (nM) 5 5 5 
Tag 99mTc 99mTc 99mTc 
    
Tumour (%ID/g)    
10 min 5.9±0.6   
1h 2.69±0.30   
3h 1.88±0.10 0.051±0.022 0.044±0.008 
5h  0.12±0.046 0.14±0.040 
16h  0.033±0.034 0.016±0.005 
22h  0.008±0.001 0.013±0.005 
    
Blood (%ID/g)    
10 min 2.27±0.25   
1h 0.11±0.00   
3h 0.03±0.00 0.027±0.002 0.024±0.001 
5h  0.14±0.04 0.19±0.04 
16h  0.005±0.001 0.009±0.001 
22h  0.004±0.001 0.007±0.004 
    
T/Blood    
10 min 2.6   
1h 24.0   
3h 62.6 1.8 1.8 
5h  0.8 0.7 
16h  6.6 1.8 
22h  2 1.8 
Table 1. In vitro characteristics and pharmacokinetics in mice for anti-TNC and anti- MUC1 
aptamers.  
6.2 Nanoparticle-aptamer conjugates for OI and NMRI 
Aptamers were also used to functionalize nanoparticles surface for a potential in vivo cell 
imaging applications (Farokhzad et al., 2004; Javier et al., 2008; Chu et al., 2006; Rong et al., 
2010; Savla et al., 2011). 
Much work has been made by using the two 2’fluoro-pyrimidine (2’Fy)-RNA aptamers (A9 
and A10) that have been generated against the extracellular domain of PSMA (prostate-specific 
membrane antigen), (Lupold et al., 2002). These aptamers bind with high affinity to the acinar 
epithelial cells of prostate cancer tissue. They have been used to deliver nanoparticles, 
quantum dots (QDs), toxin, or siRNA to prostate cancer cells (Cerchia & de Franciscis, 2010). 
www.intechopen.com
 Nucleic Acid Aptamers for In Vivo Molecular Imaging 
 
109 
Poly(D,L-lactic acid) (PLA)-PEG-COOH nanoparticles and microparticles, conjugated with 
the A10 RNA aptamer have been developed to target the (PSMA) cells in vivo (Farokhzad et 
al., 2004). 
PLA derivatives exhibit a desirable characteristic by means of their neutral to slightly 
negative surface charge, preserving the aptamers binding characteristic by specific 
interaction with them. On the opposite, particles with a positive surface charge may interact 
non specifically with the negatively charged aptamers affecting their binding properties.  
Moreover the incorporation of PEG containing a terminal hydroxyl and carboxylic acid 
functional groups results essential to maximize nanoparticle circulating half-life and to 
allow the covalent coupling with 3’-NH2–modified aptamer.  
To examine the presence of the aptamer-nanoparticle conjugates on the surface of PSMA-
positive cells, the A10 aptamer has been labeled at 5’end with FITC and uptake by LNCaP 
cells has been evaluated by fluorescent microscopy. Images taken after 2 h and 16 h of 
incubation, showed a massive internalization just after 2h of nanoparticle-aptamer 
compound versus control group (aptamer-treatment of PSMA-negative PC3 cells). 
These aptamer-nanoparticles conjugates have been loaded with docetaxel, anti-cancer 
therapeutic and successfully used for targeted delivery to PSMA-positive cells (Farokhzad et 
al., 2006). 
PSMA has been also labelled using aptamer-quantum dots conjugates (Chu et al., 2006). A 
different anti-PSMA aptamer, A9, has been selected and conjugated to luminescent CdSe 
and CdTe nanocrystals for cell labelling.  
Quantum dots (QD) represent the most promising fluorescent markers and delivery 
vehicles. These semiconductor particles have nanometre size and offer revolutionary 
fluorescence performance over traditional fluorescence dyes such as long-term 
photostability for live-cell imaging and dynamics studies, brilliant colors for simple, single-
excitation multicolor analysis, fixability for follow-up immunofluorescence after in vivo 
studies, narrow and symmetrical emission spectra for low interchannel crosstalk. 
Before conjugation the synthesized aptamer was biotinylated at its 3’-end by periodate 
oxidation and conjugation to biotin hydrazide (Qin & Pyle, 1999). 
Labeling experiments were carried out for fixed and live cells and live cells embedded in a 
collagen matrix. The A9 aptamer-QD conjugates showed specific in vitro labeling for the 
selected target exhibited a good capacity to penetrate keep into tissues.  
QD has also been conjugated with MUC1 aptamer and doxorubicin (QD-MUC1-DOX), via 
acid labile hydrazine bond, for in vivo imaging and drug delivery (Salva et al., 2011). In 
vitro and in vivo studies confirmed that the complex QD-MUC1-DOX accumulate 
predominately in the tumor and effectively release inside cancer cells (Salva et al., 2011). 
A novel, multifunctional, thermally cross-linked superparamagnetic iron oxide nanoparticle 
(TCL-SPION) which can detect prostate cancer (PCa) cells and deliver targeted 
chemotherapeutic drugs has been developed (Wang et al., 2008). TCL-SPION nanoparticle 
has been conjugated with A10 aptamer and the complex so obtained has been tested for PCa 
imaging, using a single-sided NMR probe, and therapy, loading the bioconjugate with DOX. 
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NMR studies confirm the potential of the TCL-SPION-Apt complex as a targeted MR 
contrast showing that the bioconjugate can detect PSMA-expressing PCa cells with high 
sensitivity. The Dox-loaded TLC-SPION-Apt compound has been tested for antiproliferative 
activity against both the LNCaP and PC3 cell lines. Results showed selective delivery to 
PSMA-expressing cells without loss in cytotoxicity (Wang et al., 2008).  
Further, PLA nanoparticles containing stably incorporated cyanine dyes have been tested 
for in vitro and in vivo imaging applications (Tong et al., 2010). Cy5-PLA/A10 aptamer 
nanoparticles have been found to only bind to and get internalized by LNCaP and canine 
prostate adenocarcinoma cells (PSMA-positive), but not to PC3 cells (PSMA-negative). Then, 
conjugates have been intravenously administered to balb/c mice and in vivo biodistribution 
evaluated by using the LI-COR Odyssey scanner. Accumulation of Cy5-PLA NP within 
visceral organs allows for greater than >10-fold increase in fluorescent intensity in 
comparison with background autofluorescence. Splenic accumulation of Cy5-PLA NP is the 
greatest for all visceral organs examined (spleen, liver, kidney, lung, and heart).  
Another application of the anti-PSMA A9 aptamer as molecular-specific contrast agents for 
prostate cancer imaging has been developed by Javier et al (Javier et al., 2008). The aptamer 
has been conjugated by using an extended aptamer design where the extension is 
complementary to an oligonucleotide sequence attached to the surface of gold nanoparticles. 
Binding of nanoparticle-aptamer bioconjugates to prostate LNCaP cells has been valuated 
by reflectance imaging of the labeled cells with confocal microscopy in reflectance mode. 
More recently, in vivo imaging of tumor has been performed by using the DNA aptamer sgc8, 
generated by cell-SELEX on human acute lymphoblastic leukaemia cells and identified to 
interact with protein tyrosine kinase-7 (PTK7) (Shi et al., 2011). The aptamer has been modified 
in order to generate an activatable probe consisting of the binding site of the aptamer (A-
strand), a poly-T linker and a short DNA sequence complementary to a part of the A-strand, 
with a fluorophore and a quencher attached at either terminus. In the absence of binding, the 
aptamer is in a hairpin structure resulting in a quenched fluorescence. When the probe binds 
to cell-surface receptors, it changes conformation resulting in an activated fluorescence signal. 
This molecule was intravenously injected into tumor-bearing mice and fluorescence images 
were collected. Compared to always-on aptamer probes, the activatable aptamer showed 
significantly enhanced image contrast and shortened diagnosis time to 15 min.  
6.3 Nanoparticle-aptamer conjugates for in vivo multimodal imaging  
Recently, a multimodal cancer-targeted imaging system capable of simultaneous in vivo 
fluorescence imaging, radionuclide imaging and magnetic resonance imaging in mice, has 
been reported by using the AS1411 aptamer as targeting molecule (Hwang et al., 2010). 
AS1411 aptamer is a 26-mer guanine-rich oligonucleotide (GRO), which in solution folds 
into quadruplex structures, that make it very stable and resistant to degradation by serum 
enzymes. This aptamer that binds to nucleolin, a protein that is often over-expressed on the 
surface of cancer cells, is currently in Phase II of clinical development (Bates et al., 1999, 
2009; Mongelard & Bouvet, 2010). In this study, the aptamer was conjugated with a cobalt-
ferrite nanoparticle surrounded by fluorescent rhodamine, and the resulting particle was 
bound with 2-(p-isothio-cyanatobenzyl)-1,4,7-triazacyclonane-1,4,7-triacetic acid (p-SCN-bn-
NOTA) chelating agent and further labeled with radionuclide gallium citrate Ga-67. 
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The purified nanoparticles, designated MFR-AS1411, were intravenously injected into a 
mice xenografted with nucleolin-expressing C6 rat glioma cells and radionuclide images 
were acquired at 1, 6, and 24 h after injection. Scintigraphic images of C6 tumors in mice that 
received MFRAS1411 showed that tumors had accumulated MFR-AS1411 at 24 h after 
injection whereas the mutant, not functional, MFR-AS1411 administration revealed rapid 
clearance via the bloodstream. 
Further, bioluminescence images analysed using IVIS200 system in the C6 cells, stably 
expressing the luciferase gene, illustrated the in vivo distribution. MR images of the same 
mice injected with MFR-AS1411 showed dark T2 signals inside the tumor region, compared 
with the MRI signal of the tumor region injected with mutant MFR-AS1411 particles. 
Taken together, the above results by means of multifunctional imaging modality platforms 
demonstrate that MFR-AS1411 specifically targeted cancer cells. 
7. Future perspectives 
To date only few aptamers have been developed as targeting agents in imaging modalities, 
as discussed in the present chapter and schematized in figure 4, nevertheless, their low 
immunogenicity, good tumor penetration, rapid uptake and fast systemic clearance, indicate 
a great potential of these molecules as imaging agents especially when compared to 
antibodies. Given the nature of the aptamers and their discrimination and targeting 
capacities, the majority of the aptamers not bound to the target tissues is cleared rapidly 
from the system. In comparison, intact radiolabelled antibodies remain in circulation for a 
very long time, often resulting in organ toxicity.  
 
Fig. 4. Aptamers to date developed as ligands for tumour imaging, inflammation imaging 
and thrombus imaging 
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Further, the continuous advances in SELEX technology allow now to easily generate 
aptamers against virtually any protein and it is plausible speculate that the global market 
demand for nucleic acid aptamers will increase in the next few years opening the aptamer 
field for development for therapy, diagnosis and drug development imaging. 
8. Take-home-message 
Some molecule, most notably those found in nature, have the ability to reach out and grab 
other molecules and bound to them. Aptamers appear to fulfill this criterion and have been 
identified as excellent candidates for targeting specific epitopes in clinical diagnosis and 
therapy of different diseases. Further, because of their high specificity and low toxicity 
aptamers may reveal as the compound of choice for in vivo cell recognition as delivery 
agents for nanoparticles, small interfering RNAs bioconjugates, chemotherapeutic cargos 
and molecular imaging probes (Cerchia & de Franciscis, 2010). 
There have been significant technological advances in cell-SELEX and in vivo-SELEX 
strategies. Although aptamers are relatively new to the clinic, the fact that they can act as 
specific recognition ligands to target cells in vivo suggests that these molecules will have a 
considerable impact in patient care in the near future. 
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